ahlam1399
07-20-2016, 01:18 AM
BRIEF-Sarepta Therapeutics Q2 **n-GAAP loss per share $1.19 excluding items
* ** revenue was recognized for three months ended June 30,2016 and 2015http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=ri_VOc6tf_Q:gk5S3LGB7mw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=ri_VOc6tf_Q:gk5S3LGB7mw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=ri_VOc6tf_Q:gk5S3LGB7mw:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=ri_VOc6tf_Q:gk5S3LGB7mw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=ri_VOc6tf_Q:gk5S3LGB7mw:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/ri_VOc6tf_Q
* ** revenue was recognized for three months ended June 30,2016 and 2015http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=ri_VOc6tf_Q:gk5S3LGB7mw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=ri_VOc6tf_Q:gk5S3LGB7mw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=ri_VOc6tf_Q:gk5S3LGB7mw:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=ri_VOc6tf_Q:gk5S3LGB7mw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=ri_VOc6tf_Q:gk5S3LGB7mw:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/ri_VOc6tf_Q